Compare RILY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RILY | BCYC |
|---|---|---|
| Founded | 1973 | 2009 |
| Country | United States | United Kingdom |
| Employees | 1380 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.8M | 279.9M |
| IPO Year | N/A | 2019 |
| Metric | RILY | BCYC |
|---|---|---|
| Price | $8.18 | $4.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 997.9K | 635.2K |
| Earning Date | 03-31-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.96 | $3.92 |
| 52 Week High | $11.24 | $9.18 |
| Indicator | RILY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 46.92 | 49.62 |
| Support Level | $8.17 | $3.95 |
| Resistance Level | $9.46 | $4.75 |
| Average True Range (ATR) | 0.63 | 0.18 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 54.39 | 95.31 |
BRC Group Holdings Inc is a diversified holding company offering a platform of businesses, including financial services (with complementary banking and wealth management businesses), telecom, retail, and investments in equity, debt, and venture capital. It serves retail, corporate, capital providers, and individual customers across different business lines. The Group reports its activities in seven reportable business segments: Capital Markets, Wealth Management, Lingo, magicJack, Marconi Wireless, UOL, and Consumer Products. Maximum revenue is generated from the Consumer Products segment, which offers mobile computing accessories and home furnishing products. Geographically, the Group derives its revenue from North America.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.